Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Conclusion Compared with patients treated with standard therapy, patients treated with BR reported better quality of life in several areas. Teaser Comparative chemotherapy-related quality of life data are lacking. Bendamustine-rituximab (BR) demonstrated noninferiority to R-CHOP (rituximab/cyclosphosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in first-line advanced indolent non-Hodgkin and mantle cell lymphomas. Patients receiving BR reported improvement across many domains, with a few exceptions, of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Constipation | Health | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Prednisone | Rituxan | Treanda